[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@JacobPlieth Avatar @JacobPlieth Jacob Plieth

Jacob Plieth posts on X about $jnj, $nrix, $onc, $azn the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks XXXXX% cryptocurrencies XXXXX% currencies XXXX% countries XXXX% social networks XXXX% technology brands XXXX%

Social topic influence $jnj #6, $nrix #2, $onc #1, $azn #12, $tern #11, $smmt 6.35%, $aclx #1, china 4.76%, $lly #34, $bgne #1

Top accounts mentioned or mentioned by @apexonco @avidresearch @bymadeleinea @ablt315i @bllphd @jfais20 @stlbiotech @s86coffeedev @houndcl @financebully @bananaoncology @drpaulydesantis @hartungingo @hothomaswphelps @kinatsofrim @biotwit1 @chuminhua432 @charlene_liao @hall8jack @learnbiotech

Top assets mentioned Johnson & Johnson (JNJ) One Cash (ONC) AstraZeneca PLC (AZN) Terns Pharmaceuticals, Inc. Common Stock (TERN) Summit Therapeutics Inc. Common Stock (SMMT) Arcellx, Inc. Common Stock (ACLX) Eli Lilly and Company (LLY) Janux Therapeutics, Inc. Common Stock (JANX) AbbVie Inc (ABBV) Novartis AG (NVS) Dawn Protocol (DAWN) Pfizer, Inc. (PFE) Amgen, Inc. (AMGN) Gilead Sciences, Inc. (GILD) Merck & Co., Inc. (MRK) Jazz Pharmaceuticals, Inc. (JAZZ) Revolution Medicines, Inc. Common Stock (RVMD) Allora (ALLO) BOLT Token (BOLT) Incyte Corporation (INCY) Bristol-Myers Squibb Co (BMY) Regeneron Pharmaceuticals Inc (REGN)

Top Social Posts

Top posts by engagements in the last XX hours

"$SMMT just dropping this one in casually. Note Akeso cadonilimab (PD-L1 x CTLA-4) was approved in China in Jun 2022"
X Link 2024-05-30T22:18Z 31.3K followers, 13.5K engagements

"PD-1 x VEGF meet CD47 Ivonescimab +/- ligufalimab + chemo in 1L (not dMMR) colorectal. XX% ORR. China study obv. Via Yanhong Deng #ESMO24 $SMMT $BNTX"
X Link 2024-09-14T14:05Z 31.3K followers, 23.1K engagements

"$AMGN Fortitude-101 study of bemarituzumab (ex $FPRX) + chemo is stat sig "& clinically meaningful" for OS vs chemo alone. FGFR2boverexpression (10% @ IHC 2+/3+) was enrolment criterion I believe so this is a hit on ITT. $TYRA"
X Link 2025-06-30T13:09Z 31.3K followers, 2826 engagements

"Why have not one but two VC firms now bought into anti-TROP2 ADC development @ApexOnco take on $GILD & $MRK's atypical tie-ups"
X Link 2025-11-05T14:31Z 31.3K followers, 3647 engagements

"Akeso and $IVBXF are up at #Jefferies25 shortly. Presentations not being webcast so I'll try to tweet out anything relevant"
X Link 2025-11-19T15:37Z 31.3K followers, 2430 engagements

"Akeso CFO Bing Wang: we see ivo replacing $MRK Keytruda as the anchor across several settings. Biggest market is NSCLC - anchor there w/multiple combos then expand beyond #Jefferies25 $SMMT $BNTX"
X Link 2025-11-19T16:10Z 31.3K followers, 7288 engagements

"Akeso must be one of the last fans of CD47 still standing: adding ligufalinab to ivo in head & neck doubles the ORR CFO Bing Wang tells #Jefferies25 $ALXO"
X Link 2025-11-19T16:13Z 31.3K followers, 2111 engagements

"Akeso reminds #Jefferies25 that cadonilimab (like ivonescimab) is tetravalent: X binders each for PD-1 & CTLA-4"
X Link 2025-11-19T16:18Z 31.3K followers, 2654 engagements

"Akeso claims cadonilimab is safest in class as well as first in class PD-1 x CTLA-4. So dissing $AZN (notoriously toxic) volrustomig #Jefferies25"
X Link 2025-11-19T16:27Z 31.3K followers, 1872 engagements

"GC511B appears to be an $AZN Car-T therapy against DLL3. Can anyone corroborate"
X Link 2025-11-28T15:26Z 31.3K followers, 3881 engagements

"Jaypirca shocker XX% crossover in confirmatory Bruin CLL-321 trial - obviously unavoidable and obviously trashes the OS benefit. $LLY toplined it positive for PFS which will surely confirm approval. Via Jeff Sharman #ASH24 $BGNE $ABBV $AZN $JNJ"
X Link 2024-12-09T23:35Z 31.3K followers, 13.3K engagements

"Catching up on some #ASCO25 sessions I came across this on dual-payload ADCs from Patricia LoRusso's clinical science symposium"
X Link 2025-06-06T13:09Z 31.3K followers, 6825 engagements

"Reminder: Akeso Harmoni-A interim OS hazard ratios went from XXXX - XXXX (again no p values or significance thresholds revealed). Final OS HR is likely worse than XXXX. $SMMT Harmoni interim OS HR=0.79 (p=0.057). I don't see how $SMMT p value now magically goes below 0.05"
X Link 2025-08-27T10:33Z 31.3K followers, 5052 engagements

"In 2023 $NVS paid $LEGN $100m for an anti-DLL3 Car-T. First human data at #WCLC25 show that this still a work in progress. Via @ApexOnco -"
X Link 2025-09-10T11:48Z 31.3K followers, 5920 engagements

"New players in dual-payload ADCs: Lonza Synaffix & Qurient Therapeutics. CDK7 inhibitor"
X Link 2025-09-25T07:44Z 31.3K followers, 2151 engagements

"Gammadelta T cells FTW $IPN.PA buying Imcheck for EUR350m. Approach seems not dissimilar to the now departed $LVTX"
X Link 2025-10-22T06:12Z 31.3K followers, 11.8K engagements

"Wow the Jefferies analyst really has the Akeso CFO on the ropes with her first question: "Everyone is talking about China out-licensing and it's all down to you; how do you achieve such greatness" #Jefferies25"
X Link 2025-11-19T16:03Z 31.3K followers, 9441 engagements

"@STL_Biotech That CRS prophylaxis tidbit might be the most deranged aspect of today's $JANX collapse. Wild"
X Link 2025-12-02T21:33Z 31.3K followers, 1615 engagements

"$JAZZ Ziihera data from Herizon-GEA-01 study coming at #GI26"
X Link 2025-12-03T07:45Z 31.3K followers, 2454 engagements

"$JANX ended -XX% $CTMX -11%. Here's yesterday's take from @ByMadeleineA at @ApexOnco"
X Link 2025-12-03T07:57Z 31.3K followers, 2212 engagements

"$NRIX +23% surprises me. I thought the #ASH25 data showed $ONC to be better on efficacy (with caveats) albeit worse on safety. My earlier take on @ApexOnco -"
X Link 2025-12-08T15:41Z 31.3K followers, 4841 engagements

"@ablT315I And. here come the sellside notes defending $ACLX"
X Link 2025-12-09T17:14Z 31.3K followers, XXX engagements

"$BGNE -XX% $NRIX +8%. I'm puzzled. #ASH24 data:"
X Link 2024-12-10T15:50Z 31.3K followers, 16.1K engagements

"@s86CoffeeDev @houndcl @financebully @avidresearch @Banana_Oncology $ERAS says ERAS-0015 uses different scaffold vs daraxonrasib. Not sure if that circumvents $RVMD patent"
X Link 2025-11-19T11:17Z 31.3K followers, XXX engagements

"By my calculation $ONC now has an efficacy edge vs $NRIX in BTK degradation. Caveats: small pt numbers X-trial comparison and Nurix might have the safety advantage #ASH25"
X Link 2025-12-08T11:12Z 31.3K followers, 2458 engagements

"Allogeneic FTW $CLLS $ALLO"
X Link 2023-11-28T17:00Z 31.3K followers, 4642 engagements

"$BGNE vs $NRIX in BTG degradation. I can't remember the last time I saw two separate datasets yield results that look so similar #ASH24"
X Link 2024-12-10T23:46Z 31.3K followers, 9763 engagements

"@DrPaulyDeSantis See $INBX acasunlimab (also to an extent Silverback & $BOLT) & others"
X Link 2025-07-25T08:27Z 31.3K followers, XXX engagements

"$DAWN to the rescue $MRSN"
X Link 2025-11-13T11:21Z 31.3K followers, 10.9K engagements

"What has $DAWN seen in $MRSN Via @ApexOnco -"
X Link 2025-11-13T13:32Z 31.3K followers, 3333 engagements

"Just accepted for FDA priorty review. "The treatment was well tolerated and the risks were manageable" so that's all right then $ONC"
X Link 2025-11-26T11:11Z 31.3K followers, 8512 engagements

"If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 -- Starts in just over a week $ACLX $ONC $CRVS $TERN $KURA $SNDX $CGEM $INCY"
X Link 2025-11-27T13:37Z 31.3K followers, 5863 engagements

"A year ago we were warning you that $JANX was cherrypicking data. It all seems to be unravelling today stock -50%"
X Link 2025-12-02T14:40Z 31.3K followers, 19.9K engagements

"So basically since I wrote this in Jan 2024 the $SGN $PFE patent was "revalidated" and it's just been invalidated again"
X Link 2025-12-03T11:21Z 31.3K followers, 4303 engagements

"@avidresearch Be fair though that's actually not saying a lot LOL"
X Link 2025-12-03T17:11Z 31.3K followers, 2249 engagements

"$TERN looks like the winner of #ASH25 then +37% yesterday and +600% since November's abstract lift. Funny when I last wrote about it in May it was worth a quarter of $ELVN"
X Link 2025-12-09T09:55Z 31.3K followers, 6013 engagements

"$ELVN vs $TERN: game over #ASH25"
X Link 2025-12-09T11:03Z 31.3K followers, 3982 engagements

"$LLY Jaypirca looks best. up to a point. Via @ApexOnco from #ASH25 $ONC $AZN $JNJ $ABBV $NRIX"
X Link 2025-12-09T12:45Z 31.3K followers, 4022 engagements

"Wow check out the $JNJ Tecvayli survival curves in Majestec-3 #ASH25"
X Link 2025-12-09T13:02Z 31.3K followers, 6478 engagements

"$JNJ Tecvayli (& $LEGN Carvykti) "entering a new era of resetting survival expectations in a cancer historically described as incurable". @ByMadeleineA @ApexOnco from #ASH25 on Majestec-3 $ACLX $BMY"
X Link 2025-12-09T13:05Z 31.3K followers, 5633 engagements

"@avidresearch OS even with slightly fugly crossover gives HR=0.46 $JNJ #ASH25 As ever infection risk is very real with CD3-targeting T-cell engagers"
X Link 2025-12-09T13:07Z 31.3K followers, XXX engagements

"@avidresearch Wait until you see $AZN CD8-based T-cell engagers (Perhaps.)"
X Link 2025-12-09T13:11Z 31.3K followers, 1423 engagements

"$TERN wins #ASH25 via @ApexOnco - $ELVN $NVS"
X Link 2025-12-09T14:07Z 31.3K followers, 5684 engagements

"If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage including previews here - $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA"
X Link 2025-12-09T14:41Z 31.3K followers, 4023 engagements

"What a stinker of an #ASH25 for $ACLX -XX% since Nov abstract drop. Inconsequential Immagine-1 update while others making huge strides"
X Link 2025-12-09T17:30Z 31.3K followers, 4927 engagements